Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00973765 · ClinicalTrials.gov registry record · Phase 3
Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
A Phase 3 study of Abscesses, sponsored by 59th Medical Wing.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
- 1
- Study location
NCT00973765: Completed Phase 3 study of Abscesses, sponsored by 59th Medical Wing.
NCT00973765 is a Phase 3 study of Abscesses that has completed, run by 59th Medical Wing. The registered enrollment target is 212 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00973765, a Phase 3 study of Abscesses, has completed, sponsored by 59th Medical Wing.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) placebo two tablets PO BID X 7 days or 2) bactrim DS (800/160) two tablets PO BID x 7 days. Patients will then return to the emergency department ED) at 48 hours and 7 for wound repacking and evaluation. The primary outcome is treatment failure rates at 7 days after incision and drainage. Patients who are clinically worsening or not improving after 48 hours will then be treated with additional antibiotics or admission if needed. Data will be analyzed both by initial randomization and intention to treat.
Primary Outcome
worsening abscess or new recurrence of abscess
Conditions Studied
Interventions
- DRUG placebo
- DRUG bactrim
Study Locations (1)
Texas
- Wilford Hall Medical Center - Lackland Air Force Base
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00973765 record still lists
NCT00973765 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Abscesses appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00973765 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00973765 about?
NCT00973765 is a clinical study titled "Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses". Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) placebo two tablets PO BID X 7 days or 2) bactrim DS (800/...
What is the current status of trial NCT00973765?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2007-11. Estimated completion is 2009-08.
What conditions does trial NCT00973765 study?
This clinical trial studies the following conditions: Abscesses.
What interventions are being tested in trial NCT00973765?
The interventions under investigation include: placebo (DRUG), bactrim (DRUG).
Who is sponsoring clinical trial NCT00973765?
This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00973765 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00973765's enrollment target sits among peer trials
212 1335th of 2000 higher than 664 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia